Rifaximin is a rifamycin derivative. It was developed by Italian company Alpha. It was launched in Italy in 1987 as an anti-infective diarrhea drug. It was approved by the SFDA in 2004 and has been used in China. It has the advantages of being difficult to be absorbed orally, safe, high efficiency, low residue, and no-drug period. Rifaximin uterine injection is mainly used to treat cow endometritis caused by susceptible bacteria such as staphylococcus, streptococcus, cryptococcus, escherichia coli and anaerobic bacteria.
Five new veterinary drugs "rifaximin uterine injection" are the results of joint development of Huisheng Biological and Nanjing Agricultural University. One is obtained through prescription process research, quality research, stability investigation, and clinical effect verification. And a suspension for treating cow's uterine inflammation.